Alimera Sciences, Inc.
Index- P/E- EPS (ttm)-1.02 Insider Own3.50% Shs Outstand6.99M Perf Week44.05%
Market Cap39.14M Forward P/E- EPS next Y-0.43 Insider Trans-51.40% Shs Float5.42M Perf Month13.30%
Income-6.70M PEG- EPS next Q-0.55 Inst Own26.90% Short Float0.44% Perf Quarter27.37%
Sales59.70M P/S0.66 EPS this Y36.50% Inst Trans14.85% Short Ratio0.87 Perf Half Y4.13%
Book/sh-3.98 P/B- EPS next Y56.90% ROA-11.60% Target Price12.33 Perf Year-40.98%
Cash/sh1.53 P/C3.95 EPS next 5Y- ROE33.10% 52W Range3.94 - 10.50 Perf YTD17.93%
Dividend- P/FCF- EPS past 5Y-1.10% ROI5.30% 52W High-42.38% Beta1.53
Dividend %- Quick Ratio1.90 Sales past 5Y11.40% Gross Margin88.00% 52W Low53.55% ATR0.45
Employees145 Current Ratio2.00 Sales Q/Q6.30% Oper. Margin-0.10% RSI (14)63.86 Volatility12.82% 9.36%
OptionableNo Debt/Eq- EPS Q/Q-34.40% Profit Margin-11.20% Rel Volume0.58 Prev Close5.90
ShortableYes LT Debt/Eq- EarningsMay 09 BMO Payout- Avg Volume27.72K Price6.05
Recom2.00 SMA2021.23% SMA5011.30% SMA20018.47% Volume16,065 Change2.54%
May-28-19Initiated Craig Hallum Buy
Apr-27-17Initiated Rodman & Renshaw Buy $4
Nov-17-14Initiated Summer Street Research Buy $12
Sep-29-14Reiterated Northland Capital Outperform $7 → $10
Oct-28-13Upgrade Cowen Market Perform → Outperform
Oct-08-13Initiated Northland Capital Outperform $5
Nov-14-11Downgrade Rodman & Renshaw Mkt Outperform → Mkt Perform
Dec-27-10Reiterated Oppenheimer Outperform $16 → $14
Oct-11-10Initiated Rodman & Renshaw Mkt Outperform $13
Jun-02-10Initiated Oppenheimer Outperform $16
May-12-22 08:03AM  
May-09-22 09:15AM  
May-06-22 08:00AM  
May-05-22 05:55PM  
Apr-28-22 08:30AM  
Apr-26-22 07:24AM  
Apr-06-22 08:00AM  
Mar-31-22 08:15AM  
Mar-30-22 05:44AM  
Mar-28-22 10:48AM  
Mar-02-22 08:00AM  
Mar-01-22 08:35AM  
Feb-24-22 09:25AM  
Feb-23-22 08:00AM  
Feb-17-22 08:00AM  
Feb-07-22 08:00AM  
Feb-04-22 08:00AM  
Jan-28-22 10:07AM  
Jan-05-22 08:00AM  
Dec-01-21 07:30AM  
Nov-09-21 01:16PM  
Nov-06-21 08:15AM  
Nov-05-21 10:03AM  
Oct-28-21 06:01PM  
Oct-21-21 08:00AM  
Oct-20-21 03:02PM  
Oct-13-21 08:00AM  
Sep-02-21 04:30PM  
Aug-24-21 08:00AM  
Aug-13-21 12:00PM  
Aug-10-21 08:00AM  
Aug-09-21 08:00AM  
Jul-28-21 03:03PM  
Jun-05-21 04:22AM  
May-27-21 07:15PM  
May-17-21 08:12AM  
Apr-29-21 03:30PM  
Apr-28-21 07:25PM  
Apr-26-21 10:51AM  
Apr-22-21 08:00AM  
Apr-14-21 10:34AM  
Apr-09-21 08:00AM  
Mar-18-21 08:00AM  
Mar-17-21 08:00AM  
Mar-11-21 08:00AM  
Mar-02-21 08:00AM  
Feb-25-21 03:30PM  
Feb-24-21 04:05PM  
Feb-18-21 10:57AM  
Feb-17-21 08:30AM  
Feb-15-21 08:30AM  
Feb-01-21 09:05AM  
Jan-19-21 08:00AM  
Jan-05-21 08:00AM  
Dec-24-20 09:14AM  
Dec-22-20 10:22AM  
Dec-21-20 10:13AM  
Dec-17-20 08:42AM  
Dec-16-20 01:31PM  
Dec-15-20 09:57AM  
Dec-14-20 12:59PM  
Dec-11-20 08:34AM  
Dec-10-20 09:40AM  
Dec-09-20 08:33AM  
Dec-08-20 08:56AM  
Dec-07-20 09:27AM  
Dec-04-20 08:45AM  
Dec-03-20 10:04AM  
Dec-02-20 07:42PM  
Dec-01-20 10:06AM  
Nov-27-20 08:25AM  
Nov-24-20 03:10PM  
Nov-20-20 10:08AM  
Nov-18-20 11:24AM  
Nov-16-20 08:00AM  
Nov-13-20 11:22AM  
Nov-12-20 08:00AM  
Nov-09-20 10:18AM  
Nov-06-20 10:57AM  
Nov-05-20 11:38AM  
Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MORGAN STANLEY10% OwnerFeb 08Sale4.55250,0001,137,500557,551Feb 10 09:11 PM
EISWIRTH RICHARD S JRPresident and CEODec 15Buy4.504842,177110,518Dec 16 07:36 AM
EISWIRTH RICHARD S JRPresident and CEODec 03Buy4.805,00023,981110,034Dec 07 10:33 AM
EISWIRTH RICHARD S JRPresident and CEODec 02Buy4.895,00024,428105,034Dec 06 11:24 AM
EISWIRTH RICHARD S JRPresident and CEONov 05Buy5.501,4007,700100,034Nov 08 04:01 PM
EISWIRTH RICHARD S JRPresident and CEONov 04Buy4.4110,08644,44698,634Nov 08 04:01 PM
Largent James RDirectorNov 03Buy4.3110,00043,09013,000Nov 04 08:09 PM
Jones John PhilipChief Financial OfficerNov 03Buy4.085,00020,39924,965Nov 04 04:50 PM
EISWIRTH RICHARD S JRPresident and CEONov 03Buy4.4528,005124,74588,548Nov 04 04:43 PM
Holland DavidChief Marketing Officer & SVPNov 03Buy4.085,00020,39131,130Nov 04 04:31 PM